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Abstract: 
Natural products are important sources of drug discovery. In this context groups of different set of phytochemicals were taken and docked into the 
different cavities of the Reverse transcriptase (PDB ID: 1REV) of Human immunodeficiency virus (HIV) and results were discussed. Natural compounds 
such as Curcumin, Geranin, Gallotannin, Tiliroside, Kaempferol-3-o-glucoside and Trachelogenin were found to very effective according to its binding 
energy and ligand efficiency score. Those compounds also were found to have no adverse effect as carcinogenicity and mutagenicity and favorable drug 
likeness score. Hence, considering the facts those compounds could use effectively for HIV-1 drug discovery. 
 
 
 
 
 
Background: 
Human immunodeficiency virus (HIV) is a lentivirus (a member of the 
retrovirus family) that causes acquired immunodeficiency syndrome 
(AIDS), [1-2] a condition in humans in which the immune system begins 
to fail, leading to life-threatening opportunistic infections. Once HIV 
enters the human body, its primary target is a subset of immune cells that 
contain a molecule called CD4. In particular, the virus attaches itself to 
CD4+T cells and, to a lesser extent, to macrophages. Reverse Transcriptase 
(RT) converts the single-stranded HIV RNA genome to a double-stranded
 
DNA copy by catalyzing both DNA-dependent and RNA-dependent DNA
 
polymerization as well as RNase H cleavage activity to remove
 the RNA 
template once the DNA has been synthesized. Because of
  its unique 
catalytic properties, RT has been the target enzyme
  for many antiviral 
therapeutic agents used in the treatment of
 AIDS, including nucleoside and 
nonnucleoside analogues [3-6].  
 
The aim of molecular docking is to evaluate the feasible binding 
geometries of a putative ligand with a target whose target site is known. 
The binding geometries is often known as binding poses, includes, in 
principle, both the position of the ligand relative to the receptor and 
conformational state of the ligand and the receptor. There are three basic 
tasks any docking procedure must accomplish: (1) characterization of the 
binding site; (2) positioning of the ligand into the binding site (orienting); 
and (3) evaluating the strength of interaction for a speciﬁc ligand-receptor 
complex (“scoring”). The ﬁrst challenge for computer-aided design is to 
identify one or more lead compounds that show activity in an appropriate 
assay. Until recently most drugs in the market come from the lead 
compounds discovered by screening of natural products or exploring the 
analogues of known structures. 
 
There are many small molecule databases in public domain such as ZINC, 
Pubchem, ChemDB, ChemSpider, KEGG ligand database and DrugBank 
for virtual screening. The procedure of structure based virtual screening 
through docking has become crucial when it is necessary to test a database 
of thousands of compounds against one or more protein targets in a 
feasible time. 
 
An increasing number of patients with HIV infection cannot use the 
currently approved anti-HIV drugs, including the reverse transcriptase and 
protease inhibitors, due to the adverse effects and the emergence of drug 
resistance, the search for new effective and safe as well as affordable anti-
HIV agents is not merely an academic curiosity but rather a necessity [7]. 
It is important to note that a number of promising anti-HIV natural 
products have made it to the clinical level and are anticipated to be 
available to patients very soon [7]. The following natural products can be 
cited as promising anti-HIV agents of plant origin: baicalin (a ﬂavonoid) 
[8], calanolides (coumarins) [9], betulinic acid (a triterpene) [10-11], 
polycitone A (an alkaloid) [12], lithospermic acid, sulphated 
polysaccharides, cyanovirin-N [13], pokeweed antiviral protein [14] and 
alpha-trichobitacin (proteins). In this context six different set of 
phytochemicals were taken and docked into the cavities of the Reverse 
transcriptase and results were discussed.  
 
Methodology: 
The three dimensional structure of target HIV reverse transcriptase 
(PDBID: 1REV) was retrieved from protein data bank at 2.6 Ǻ RMSD 
resolution. Phytochemicals with anti-HIV activity such as Curcumin, 
Geranin, Gallotannin, Tiliroside, Kaempferol-3-o-glucoside and 
Trachelogenin were obtained from Dr. Duke database (http://www.ars-
grin.gov/duke/), which were searched against pubchem and chemspider 
database for the 2D structures and then with the help of open babel 
[http://openbabel.org/wiki/Main_Page] these 2D structures are converted 
to 3D structures. The 3D structures which are obtained are minimized 
using Hyperchem’s MM+ force field.   Molegro Virtual Docker [15] was 
used to detect the active sites and docking was performed by moldock 
function, which is an implementation of evolutionary algorithms (EAs), 
focused on molecular docking simulations. Docking was performed with 
all the potential active sites detected on HIV reverse transcriptase enzyme.  
During Docking at first the molecules were prepared and bonds, bond 
orders, explicit hydrogens, charges, flexible torsions, were assigned if they 
were missing by the MVD program to both the protein and ligands. From 
the docking wizard ligands were selected and the scoring function used is 
Moldock score. The Ignore distant atoms option is used to ignore atoms far 
away from the binding site. It reduces overall computing time. The Enforce 
hydrogen bond directionality option is used to check if bonding between 
potential hydrogen bond donors and acceptors can occur. If hydrogen 
bonding is possible, the hydrogen bond energy contribution to the docking 
score is assigned a penalty based on the deviations from the ideal bonding Bioinformation  Volume 5  open access 
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angle. Using this option can significantly reduce the number of unlikely 
hydrogen bonds reported also internal electrostatic interaction, internal 
hydrogen bond sp2-sp2 torsions are calculated from the pose by enabling 
the ligand evaluation terms. The search algorithm is taken as Moldock SE 
and numbers of runs are taken 10 and max iterations were 2000 with 
population size 50 and with an energy threshold of 100 also at each step 
least 'min' torsions/translations/rotations are tested and the one giving 
lowest energy is chosen. If the energy is positive (i.e. because of a clash or 
an unfavorable electrostatic interaction) then additional 'max' positions will 
be tested. Pose clustering was done by tabu based clustering method, using 
this clustering technique each found solution is added to a 'tabu list': during 
the docking simulation the poses are compared to the ligands in this 'tabu 
list'. If the pose being docked is closer to one of the ligands in the list than 
specified by the RMSD threshold, an extra penalty term (the Energy 
penalty) is added to the scoring function. This ensures a greater diversity of 
the returned solutions since the docking engine will focus its search on 
poses different from earlier poses found. The energy penalty was set to 
100, RMSD threshold was 2.00 and RMSD calculation by atom ID (fast) 
were set. 
 
After the docking simulation is over the poses which were generated were 
sorted by rerank score. The Rerank Score uses a weighted combination of 
the terms used by the MolDock score mixed with a few addition terms (the 
Rerank Score includes the Steric (by LJ12-6) terms which are Lennard-
Jones approximations to the steric energy – the MolDock score uses a 
piecewise linear potential to approximate the steric energy) [15]. The 
reranking score function is computationally more expensive than the 
scoring function used during the docking simulation but it is generally 
better than the docking score function at determining the best pose among 
several poses originating from the same ligand [15]. Ligand efﬁciency is 
most commonly deﬁned as the ratio of the free energy of binding over the 
number of heavy atoms in a molecule [18]. Binding affinities were 
calculated using Molegro data modeler and MVD used to find Ligand 
Efficiency 1(LE 1) as Moldock score divided by Heavy Atoms count, 
ligand efficiency 2(LE2) as a result of binding Affinity divided by Heavy 
Atoms count and Ligand Efficiency 3 (LE 3) as rerank Score divided by 
Heavy Atoms count.  
 
The coefficients for the binding affinity terms were derived using multiple 
linear regression. The model was calibrated using a data set of more than 
200 structurally diverse complexes from the PDBbind database with 
known binding affinities (expressed in kJ/mol) [16]. The Pearson 
correlation coefficient was 0.60 when doing 10-fold cross validation. It is 
important to note that this particular model was trained only on strongly 
interacting ligands in their optimal conformation known from the PDB 
complexes. Since the binding affinity measure was trained using known 
binding modes only, it might sometimes assign too strong binding 
affinities to weakly or non-binding molecules (false positives). Therefore 
recommend ranking the results of a virtual screening run using the rerank 
score. The binding affinity measure may then be used subsequently to get a 
rough estimate of the highest ranked poses.  
The scoring function used by MolDock is derived from the piecewise 
linear potential (PLP) scoring functions [17]. The scoring function used by 
MolDock further improves these scoring functions with a new hydrogen 
bonding term and new charge schemes [15]. Based on evolutionary 
agorithms (EAs) classification moldock algorithm may be classified as an 
Evolutionary simulator (ES), since it employs direct ranking of the 
solutions and the crossover operators. MolDock showed better overall 
performance in docking simulations when compared with other software.  
 
ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) 
properties were predicted using PreADMET server 
(http://preadmet.bmdrc.org/) to know whether the phytochemicals has the 
potential of adverse effect in human.  
 
 
Figure 1: Five cavities detected in reverse transcriptase enzyme (PDB ID: 1REV) Bioinformation  Volume 5  open access 
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Figure 2: Structure of compounds used for docking study. (a) Trachelogenin (b) Curcumin (c) Geraniin (d) Kaempferol-3-O-Glucoside (e) Gallotannin (f) 
Tiliroside 
 
 
Figure 3: Different ligands at highly bound cavity. (a)  cucurmin  in  cavity  1, (b) geranin in cavity 2, (c)kaempferol-3-o-glucoside in cavity 5, (d) 
gallotannin in cavity 3, (e) tiliroside in cavity 1, (f) trachelogenin in cavity 1 Bioinformation  Volume 5  open access 
www.bioinformation.net  Issue 10  Hypothesis
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Results and Discussion: 
A total of five cavities (Figure 1) were able to detected in reverse 
transcriptase enzyme (PDB ID: 1REV) by using Molegro Virtual Docker 
and  were named cav1, cav2, cav3, cav4 and cav5, the volume and surface 
area details were given as Table 1(see Supplementary material). Details 
of five cavities are given in Table 4(see Supplementary material). 
 
Reverse Transcriptase has, there are two p66 domains and one p51 domain. 
p66 and p51 share a common amino terminus; p66 is 560 amino acids in 
length, p51 is 440 amino acids long.  The larger subunit of the RT 
heterodimer, p66, contains the active sites for both of the enzymatic 
activities of RT (polymerase and RNase H); the smaller subunit plays a 
structural role. p66 is composed of two spatially distinct domains, 
polymerase and RNase H. The polymerase domain is composed of four 
subdomains: fingers (residues 1–85 and 118–155), palm (residues 86–117 
and 156–236), thumb (237–318), and connection (319–426). The nucleic-
acid binding cleft is formed primarily by the p66 fingers, palm, thumb, 
connection, and RNase H subdomains of p66. The polymerase active site is 
composed of three catalytic carboxylates in the palm subdomain of p66 
(D110, D185, and D186) that bind two divalent ions [19]. The cavity 5 has 
such residues in them and the residue shows their contributions to their 
inhibitors. 
 
Curcumin is mainly found  in  Curcuma longa, Curcuma xanthorrhiza, 
Curcuma zedoaria, Costus speciosus and Zingiber officinale. Geranin is 
found in Phyllanthus amaru,  Erythroxylum coca var. coca,  Geranium 
thunbergii, Spondias pinnata and Terminalia catappa. Gallotannin is found 
in following plants  Camellia sinensis, Salvia officinalis, Arctostaphylos 
uva-ursi, Juniperus communis, Rosmarinus officinalis, Vaccinium 
myrtillus, Ginkgo biloba, Prunus cerasus, Psidium guajava, Thymus 
vulgaris, Plantago major, Urtica dioica, Achillea millefolium, Equisetum 
arvense, Fragaria spp, Terminalia catappa, Cynara cardunculus subsp. 
Cardunculus and Glechoma hederacea. The compound tiliroside is found 
in  Althaea officinalis, Helianthemum glomeratum, Pteridium aquilinum, 
Rosa spp, Tilia sp.  Trachelogenin found in Arctium lappa and Cnicus 
benedictus.  The compound kaempferol-3-o-glucoside found in  Vitis 
vinifera, Urtica dioica and Echinacea spp. Structures of each compound is 
displayed in Figure 2.  
 
All the phytochemicals were used as ligand at mentioned 5 cavities of   
reverse transcriptase enzyme (PDB ID: 1REV) and the results of the top 
ligands whose rerank score > -100 were selected and which were given in 
Table 2(a-e) (see Supplementary material) of the context along with the 
hydrogen bond interaction values, the hydrogen bond number and other 
electrostatic interaction values. Binding pose of each ligand at their highly 
bound cavity is showed in figure 3. Selected phytochemicals were studied 
with potential Anti HIV compound 4,5,6,7-tetrahydroimidazo[4,5,1-
jk][1,4]benzodiazepin-2(1H)-thione (TIBO) [20] and rerank score and 
moldock score were found to be good than (TIBO) (Table 5 see 
Supplementary material).  A study also conducted by using similar 
structural analogue of ligands in all the cavities and phytochemicals 
showed higher binding score than structural analogue (Table 6 see 
Supplementary material).  
 
The molecules were searched for Lipinski rule of 5, lead like rule, CMC 
like rule, MDDR like rule, WDI like rule, Reactive functional group for 
drug likeness. Typical ADME prediction methods involves Caco-2cell 
permeability, Madin-Darby Canine Kidney Cell Permeability (MDCK), 
Human Intestinal Absortion (HIA), Skin Permeability, Blood-Brain Barrier 
(BBB) penetration were also calculated for the molecules along with the 
mutagenicity and carcinogenicity test based on Ames Test using 
PreADMET online webserver (http://preadmet.bmdrc.org/). The results of 
ADMET and drug-likeness are given as Table 3 (see Supplementary 
material). All the phytochemicals were bound to its target with rerank 
scores ranging from -100.56 to -136.23 at multiple binding sites on the 
enzyme. ADMET prediction resulted any carcinogenic effects in selected 
compounds. Trachelogenin found to be mutagenic by Ames test model of 
preADMET  (Table 3 see Supplementary material). These results will 
probably become a lead phytochemical for further drug discovery process. 
 
References: 
[1]  RA Weiss, Science (1993) 260: 5112 [PMID 8493571]  
[2]  DC Douek et al. Annu Rev Med. (2009) 60: 471 [PMID 18947296] 
[3]  E De Clercq, Biochem Pharmacol. (1994) 47: 155 [PMID: 7508227] 
[4]  E De Clercq, Clin  Microbiol  Rev. (1997) 10: 674  [PMID: 9336668]  
[5]  SP Goff, J Acquired Immune Defic Syndr. (1990) 3: 817  [PMID: 
1694894] 
[6]  H Mitsuya et al. Science (1990) 249: 4976 [PMID: 1699273] 
[7]  K Asres et al. Phytother Res. (2005) 19: 557 [PMID: 16161055] 
[8]  K Kitamura et al. Antivir Res. (1998) 37: 131 [PMID: 9588845] 
[9]  P Zhou et al. Phytochemistry (2000) 53: 689 [PMID: 10746882] 
[10]  RH Cichewicz & SA Kouzi, MedRes Rev. (2004) 24: 94 [PMID: 
14595673] 
[11]  SL Holz-Smith et al. Antimicrob Agents Chemother. (2001) 45: 60 
[PMID: 11120945] 
[12]  S Loya et al. Biochem J. (1999) 344: 85 [PMID: 10548537] 
[13]  B Dey et al. J Virol. (2000) 74: 4562 [PMID: 10775592] 
[14]  FM Uckun et al.  Antimicrob Agents Chemother. (1998)  42: 383 
[PMID: 9527790] 
[15]  R Thomsen & MH Christensen, J Med Chem. (2006) 49: 3315 
[PMID: 16722650] 
[16]  R Wang et al. J  Med  Chem. (2004) 47: 2977 [PMID: 15163179]. 
[17]  JM Yang & CC Chen, Proteins (2004) 55: 288 [PMID: 15048822] 
[18]  C Abad-Zapatero & JT Metz, Drug Discov Today. (2005) 10: 464 
[PMID: 15809192] 
[19]  SG Sarafianos et al. J Mol Biol. (2009) 385: 693 [PMID: 19022262] 
[20]  R Pauwels et al.  Nature (1990) 343: 6257 [PMID: 1689015]
 
 
Edited by A Cherkasov 
Citation: Seal et al. Bioinformation 5(10): 430-439 (2011) 
License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial 
purposes, provided the original author and source are credited. 
 
 
 
 
 
 
 
 
 
 
 
 
 Bioinformation  Volume 5  open access 
www.bioinformation.net  Issue 10  Hypothesis
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 5(10): 430-439 (2011)                         © 2011 Biomedical Informatics 
 
 
434
Supplementary material: 
 
Table 1: Cavity information of enzyme (1REV.pdb) 
Cavity Name  Volume(Ǻ
3) Surface  Area(Ǻ
2) 
Cav1 497.664  1689.6 
Cav2 425.984  1276.16 
Cav3 387.584  1290.24 
Cav4 365.568  1058.56 
Cav5 342.016  912.64 
 
Table 2(a):  Docking result at Cavity one 
Ligand name  Molecular 
formula 
MolDock 
Score 
Rerank 
Score 
No of 
H 
Bond 
HBond 
Energy 
Binding
Affinity 
Ligand efficiency  Interacting_Residues 
LE1 LE2  LE3 
Curcumin C21H20O6  -144.75  -110.84  7  -5.87  -11.22  -5.36  -0.41  -4.10  Gln 161, Gln 161, Pro 140, 
Thr 139, Ser 134, Ser 134, 
Val 381 
Geraniin C41H28O27  -121.93  -110.14  11  -14.14  5.14  -1.79  0.08  -1.62  Gln 23, Gln 23, Gln 23, Gln 
23, Pro 25, Ile 94, Asn 137, 
Gly 93, Pro 140, Gly 91, Lys 
22 
Gallotannin C27H24O18  -150.38  -111.14  15  -16.01  1.82  -3.34  0.04  -2.47  Gln 91, Pro140,Thr 139, Asn 
137, Ser134, Gln 23 , Val 21, 
Asn 57 
Tiliroside C30H26O13  -183.39  -134.95  14  -15.23  -8.27  -4.26  -0.19  -3.14  Tyr 181, Val 381, Ile 132, 
Pro 140 ,Gln 23, Asn 137, 
Ser 134, Asn 136, Thr 139, 
Gln 182 
Kaempferol-3-
o-glucoside 
C21H20O11  -153.02  -110.3  12  -10.40  -11.47  -4.78  -0.36  -3.45  Asn 137 ,Ile132,Pro 140 
,Gln23, Leu26, Ser 134,Thr 
139 
Trachelogenin C21H24O7  -128.58  -107.07  3  -6.82  -19.37  -4.59  -0.69  -3.82  Ser 134, Gln 23, Gln 91 
 
Table 2(b). Docking result at Cavity two 
Ligand 
name 
Molecular 
formula 
MolDock 
Score 
Rerank 
Score 
No of 
H 
Bond 
H Bond  Binding 
Affinity 
     Ligand efficiency  Interacting Residues 
LE1 LE2  LE3 
Geraniin C41H28O27  -217.3  -136.23  19  -18.44  -8.37  -3.20  -0.12  -2.00  Phe 87, Phe 87, Phe 87, Gly 384, 
Thr 386, Thr 386, Glu 413, Glu 
413, Glu 413, Tyr 183, Tyr 183, 
Tyr 181, Ile 411, Ile 411, Gln 182, 
Gln 182, Gln 182, Lys 154, Glu 
413 
Gallotannin C27H24O18  -166.53  -123.11  5  -18.80  -2.87  -3.70  -0.06  -2.74  Tyr 181, Asn 81, Lys 154, Gln 182  
Tiliroside C30H26O13  -168.47  -111.34  10  -9.75  -4.73  -3.92  -0.11  -2.59  Gln 161, Ala 158, Phe 87, Pro 95, 
Ile 94,Tyr 181, Gln 182,Met 184 
 
Table 2(c) Docking result at Cavity three  
Ligand name 
 
Molecular 
formula 
MolDock 
Score 
Rerank 
Score 
No of 
H 
Bond 
H 
Bond 
Binding 
Affinity 
     Ligand efficiency  Interacting Residues 
LE1 LE2  LE3 
Gallotannin C27H24O18  -155.14  -128.16  4  -17.61  1.60  -3.45  0.04  -2.85  Arg 172, Gly 141, Arg 143, Gln 
161 
Trachelogenin   C21H24O7  -136.75  -104.60  11  -10.46  -19.38  -4.88  -0.69  -3.74  Glu 169,  Lys 173, Glu 89, Gly 
141, Pro 140, Thr 39, Glu 42,  
Tyr 144, Ile 50 
 
Table 2(d): Docking result at Cavity four 
Ligand name  Molecular 
formula 
MolDock 
Score 
Rerank 
Score 
No 
of H 
Bond 
H 
Bond 
Binding 
Affinity 
     Ligand efficiency  Interacting_Residues 
LE1 LE2 LE3 
Gallotannin C27H24O18  -132.75  -109.48  7  -22.01  -0.78  -2.95  -0.02  -2.43  Gln 507, Glu 404, Trp 406, Lys 
431, Tyr 532             Bioinformation  Volume 5  open access 
www.bioinformation.net  Issue 10  Hypothesis
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Tiliroside C30H26O13  -182.88  -127.85  16  -11.83  -9.18  -4.25  -0.21  -2.97  Gln 500, Gly 504, Arg 354, His 
361, Lys 366,Trp 406,Gly 
504,Glu 404, Gln 507, Asn 418, 
Thr 419,Pro 420 
Kaempferol-3-
o-glucoside 
C21H20O11  -140.62  -100.56  9  -10.87  -10.63  -4.39  -0.33  -3.14  Glu 430, Leu 533, Tyr 532, Gln 
509, Gln 507, Lys 431,Glu 404     
 
Table 2(e): Docking result at Cavity five 
Ligand name  Molecular 
formula 
MolDock 
Score 
Rerank 
Score 
No of 
H 
Bond 
H Bond  Binding 
Affinity 
     Ligand efficiency  Interacting_Residues 
LE1 LE2  LE3 
Kaempferol-3-o-
glucoside 
C21H20O11  -168.548  -118.36  8  -5.709  -6.038  -5.26  -0.18  -3.69  Trp 410, Asp 186, Gln 407, 
Tyr 232, Tyr 354, Glu 370  
Gallotannin C27H24O18  -167.67  -127.30  11  -13.12  -1.66  -3.72  -0.04  -2.83  Gln 373, Gly 231,Tyr 232 , 
Glu 233, Arg 358,Tyr 405, 
Gln 407, Lys 366, Glu 404 
Tiliroside C30H26O13  -196.749  -133.33  5  -3.39  -3.61  -4.58  -0.08  -3.1  Glu 370,Tyr 232, Gly 231, 
Gln 407 
Trachelogenin   C21H24O7  -119.203  -102.71  3  -4.07  -18.29  -4.26  -0.65  -3.67  Glu 233, Gln 407,Tyr 232 
 
Table 3. Toxicity and Drug-likeness report of the molecule 
Ligand Formula  CMC 
like 
rule 
Lead 
like rule 
MDDR 
Rule 
Rule of 
5 
WDI 
Rule
 
HIA% C2C   
Permeability 
(nm/sec) 
MDCK 
(nm/sec) 
Logkp 
cm/hr 
PPB 
(%) 
BBB
c.brain/ 
c.blood 
AMES 
test 
Curcumin   C21H20O6 Q
  violated MS  Suitable out  of 
90% 
cutoff 
76.07 19.18  25.52  -3.85 70.35 0.2612  NM 
Geraniin C41H28O27 NQ  violated  MS  violated out  of 
90% 
cutoff 
0 16.51  0.0434  -4.76  4.3979  0.027001  NM 
Kaempferol-3-
o-glucoside 
C21H20O11 NQ  violated  MS  violated out  of 
90% 
cutoff 
6.46 11.51  0.468  -5.141  30.74  0.029  NM 
Gallotannin C27H24O18 NQ  violated  MS  violated out  of 
90% 
cutoff 
0 8.95  13.73  -5.005  7.37  0.02718  NM 
Tiliroside C30H26O13 NQ  violated  MS  violated out  of 
90% 
cutoff 
6.182 15.92  0.396  -4.99 36.84 0.03101 NM 
Trachelogenin   C21H24O7 Q  violated MS  Suitable  In 
90% 
cutoff 
83.26 24.63  1.989  -4.403  47.399  0.08727 M 
Carcinogenity (Mouse), Carcinogenity (Rat) result of all the compound found as negative. NQ = Not qualified, Q = Qualified, MS = Mid-Structure, NM = 
Non-Mutagen, M = Mutagen, HIA
 = Human Intestinal Absorption, PPB = Plasma Protein Binding, BBB
 = Blood Brain Barrier, C2C
 = CaCo 2 Cell, 
MDCK
 = Madin-Darby canine kidney cell, WDI
 = World Drug Index 
 
Table 4:  
(a)  Cavity 1:  (b)  Cavity 2: 
Secondary  
strucure 
Target  
Atoms:Molecule 
Residue 
ID 
Secondary  
strucure 
Target  
Atoms:Molecule 
ResidueID 
 C  1REV [B]  Val 21  H  1REV [B]  Phe77 
C  1REV [B]  Lys22  H  1REV [B]  Arg78 
C  1REV [B]  Gln23  H  1REV [B]  Glu79 
C  1REV [B]  Trp24  H  1REV [B]  Asn81 
C  1REV [B]  Pro25  H  1REV [B]  Lys82 
H  1REV [B]  Leu26  C  1REV [B]  Gln85 
H  1REV [B]  Ile31  C  1REV [B]  Asp86 
C 1REV  [B]  Asn57  C 1REV  [B]  Phe87 
C 1REV  [A]  Trp88  C 1REV  [B]  Trp88 
C 1REV  [A]  Glu89  C 1REV  [B]  Leu92 
C 1REV  [A]  Val90  C 1REV  [B]  Ile94 
C 1REV  [A]  Gln91  C 1REV  [B]  Pro95 
C 1REV  [A]  Leu92  C 1REV  [B]  His96 
C  1REV [A]  Gly93  H  1REV [B]  Lys154 
C  1REV [A]  Ile94  H  1REV [B]  Gly155 
C  1REV [A]  Pro95  H  1REV [B]  Pro157 
C  1REV [A]  His96  H  1REV [B]  Ala158 
E  1REV [B]  Thr131  H  1REV [B]  Ile159 
E  1REV [B]  Ile132  H  1REV [B]  Gln161 Bioinformation  Volume 5  open access 
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C  1REV [B]  Pro133  H  1REV [B]  Ser162 
T  1REV [B]  Ser134  C  1REV [B]  Tyr181 
T  1REV [B]  Ile135  C  1REV [B]  Gln182 
C  1REV [B]  Asn136  T  1REV [B]  Tyr183 
T  1REV [B]  Asn137  C  1REV [B]  Met184 
T  1REV [B]  Thr139  C  1REV [B]  Tyr319 
C 1REV  [B]  Pro140  C 1REV  [B]  Trp383 
C 1REV  [B]  Gly141  C 1REV  [B]  Gly384 
H  1REV [A]  Gln161  C  1REV [B]  Lys385 
C 1REV  [A]  Tyr181  C 1REV  [B]  Thr386 
C 1REV  [A]  Gln182  C 1REV  [B]  Pro387 
T 1REV  [A]  Tyr183  E 1REV  [B]  Lys388 
C 1REV  [A]  Tyr232  C 1REV  [B]  Ile411 
E  1REV [A]  Lys350  C  1REV [B]  Pro412 
H  1REV [A]  Thr377  C  1REV [B]  Glu413 
H 1REV  [A]  Glu378       
H 1REV  [A]  Ile380       
H 1REV  [A]  Val381       
H 1REV  [A]  Ile382       
H 1REV  [A]  Gly384       
 
 (c) Cavity 3:  (d) Cavity 4:  (e) Cavity 5: 
Secondary 
structure 
Target 
Atoms:Molecule 
ResidueID Secondary 
structure 
Target 
Atoms:Molecule 
ResidueID Secondary 
structure 
Target 
Atoms:Molecule 
ResidueID 
C  1REV [B]  Val21  C  1REV [A]  Arg358  C  1REV [B]  Ile63 
C  1REV [B]  Lys22  C  1REV [A]  Gly359  C  1REV [B]  Lys64 
C  1REV [B]  Gln23  C  1REV [A]  Ala360  T  1REV [B]  Lys65 
C  1REV [B]  Trp24  C  1REV [A]  His361  C  1REV [B]  Lys66 
C  1REV [B]  Pro25  C  1REV [A]  Thr362  C  1REV [B]  Arg72 
C  1REV [B]  Leu26  H  1REV [A]  Asn363  C  1REV [B]  Val108 
H  1REV [B]  Ile31  H  1REV [A]  Lys366  B  1REV [B]  Leu109 
H  1REV [B]  Glu42  H  1REV [A]  Trp401  T  1REV [B]  Asp110 
B  1REV [B]  Ser48  H  1REV [A]  Glu404  T  1REV [B]  Asp186 
C  1REV [B]  Lys49  H  1REV [A]  Tyr405  C  1REV [B]  Tyr188 
C  1REV [B]  Ile50  C  1REV [A]  Trp406  C  1REV [B]  Gly231 
T  1REV [B]  Gly51  C  1REV [B]  Asn418  C  1REV [B]  Tyr232 
C  1REV [B]  Pro52  C  1REV [B]  Thr419  C  1REV [B]  Glu233 
C  1REV [B]  Asn57  C  1REV [B]  Pro420  C  1REV [B]  Tyr354 
C  1REV [A]  Trp88  C  1REV [B]  Pro421  C  1REV [B]  Met357 
C  1REV [A]  Glu89  C  1REV [B]  Leu425  C  1REV [B]  Arg358 
C  1REV [A]  Val90  C  1REV [A]  Gln428  H  1REV [B]  Lys366 
C  1REV [A]  Gln91  C  1REV [A]  Leu429  H  1REV [B]  Thr369 
E  1REV [B]  Thr131  C  1REV [A]  Glu430  H  1REV [B]  Glu370 
E  1REV [B]  Ile132  C  1REV [A]  Lys431  H  1REV [B]  Ala371 
C  1REV [B]  Pro133  C  1REV [A]  Glu432  H  1REV [B]  Gln373 
C  1REV [B]  Ser134  H  1REV [A]  Gln500  H  1REV [B]  Lys374 
C  1REV [B]  Ile135  H  1REV [A]  Tyr501  H  1REV [B]  Thr377 
C  1REV [B]  Asn136  H  1REV [A]  Leu503  T  1REV [B]  Glu404 
T  1REV [B]  Asn137  H  1REV [A]  Gly504  T  1REV [B]  Tyr405 
C  1REV [B]  Thr139  H  1REV [A]  Ile505  T  1REV [B]  Trp406 
C  1REV [B]  Pro140  H  1REV [A]  Ile506  C  1REV [B]  Gln407 
C  1REV [B]  Gly141  H  1REV [A]  Gln507  C  1REV [B]  Ala408 
B  1REV [B]  Ile142  H  1REV [A]  Ala508  C  1REV [B]  Thr409 
C  1REV [B]  Arg143  T  1REV [A]  Gln509  C  1REV [B]  Trp410 
H  1REV [A]  Ala158  C  1REV [A]  Pro510       
H  1REV [A]  Gln161  C  1REV [A]  Val531       
H  1REV [A]  Ser162  B  1REV [A]  Tyr532       
H  1REV [A]  Thr165  C  1REV [A]  Leu533       
H  1REV [A]  Lys166  C  1REV [A]  Ala534       
H 1REV  [A]  Glu169             
H 1REV  [A]  Arg172             
H 1REV  [A]  Ile380             
H 1REV  [A]  Val381             
H 1REV  [A]  Ile382             
C= Coil T = turn , H= alpha Helix E beta sheet B = beta bridge 
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Table 5: Rerank score of TIBO and phytochemicals, Rerank score better than TIBO showed as bold. 
Name of ligands  Cavity 1   Cavity 2   Cavity 3   Cavity 4   Cavity 5 
TIBO  -88.0895  -78.1128 -101.874 -96.8846  -92.4498 
CURCUMIN  -110.836 -85.8405  -99.9434  -98.7942  -72.57 
GERANIIN  -110.141 -136.227  -56.3255 -87.5479  -63.0893 
KAEMPFEROL-3-O-
GLUCOSIDE 
-110.3 -86.413  -97.4775  -100.557  -118.36 
GALLOTANNIN  -111.141  -123.105 -128.155 -109.482  -127.304 
TILIROSIDE  -134.951 -111.342  -98.9275  -127.852 -133.33 
TRACHELOGENIN  -107.071  -87.4864 -104.603 -99.9473  -102.709 
 
Table 6: (a) Curcumin and its derivatives at cavity 1 
Sl. No  Ligand Name  SMILES  Rerank score 
1 Curcumin  OC(C1)(c(o)o)CC(O)C(O)C1OC(O)CCC(C2)CCC(O)C2O  -110.836 
2 4-[5-(aminomethyl)-7-(4-chloro-3-methylcyclohex-3- 
en-1-yl)-3-methylheptyl]-2-methylcyclohex-1-en-1-ol 
ClC(=C(C)C1)CCC1CCC(C[NH3+])CC(C)CCC(C2)CCC(O)
=C2C 
-96.3325 
3 4-chloro-6-[3-(hydroxymethyl)cyclohex-3-en-1-yl]-2- 
{2-[4-(hydroxymethyl)cyclohex-3-en-1- 
yl]ethyl}hexan-1-ol 
ClC(CCC1CC(CO)=CCC1)CC(CO)CCC(CC=2)CCC=2CO -99.7003 
4 1-[4-chloro-3-(hydroxymethyl)cyclohex-3-en-1-yl]-7- 
[4-(hydroxymethyl)cyclohex-3-en-1-yl]heptane-3,5-
diol 
ClC(=C(C1)CO)CCC1CCC(O)CC(O)CCC(CC=2)CCC=2CO -105.156 
5   4-[7-(3-amino-4-methylphenylidene)heptyl]-2- 
chloroaniline 
Clc([cH]1)c(N)[cH][cH]c1CCCCC[CH]C=c([cH]2)[cH][cH]c
(C)c2N 
-100.938 
6 (1S,2S,5S)-2-chloro-5-[(3R,5R)-3,5-diamino-7-[4- 
(hydroxymethyl)cyclohexyl]heptyl]cyclohexan-1-ol 
ClC(C(O)C1)CCC1CCC(N)CC(N)CCC2CCC(CO)CC2 -102.884 
 
Table 6: (b) Geraniin and its derivatives at cavity 2. 
Sl. No  Ligand Name  SMILES  Rerank Score 
1 Geraniin  OC(O1)(C2(O)O)C(O)CC(C(O)OC43)C2C5C1C(O)C(O)CC5C(O)O
C6C3OC(O)C7CC(O)C(O)C(O)C7C8C(O)C(O)C(O)CC8C(O)OCC4
OC6OC(O)C(C9)CC(O)C(O)C9O 
-136.227 
2 (1S,38S)-28-[hydroxy(3,4,5-trihydroxy-2- 
methylphenyl)methoxy]-2,20-dimethyl-
6,9,27,30,40- pentaoxa-24- 
azaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{
8,29}.0^{11,16}.0^{17,22}.0^{32,37}]tetra
conta- 17(22),18,20,32,34,36-hexaen- 
5,15,18,19,34,35,39,39-octol 
OC1(O)C2c3c(CO4)[cH]c(O)c(O)c3OC1C(C)CC2C(O)OC5C(O6) 
CNCc7[cH]c(C)c(O)c(O)c7C8C(O)CCCC8COC5C4C6OC(O)c9[cH]
c(O)c(O)c(O)c9C 
-130.206 
3 (1S,8S,29R,38S)-2-[(S)- 
amino(methyl)hydroxysulfanyl]-1,35-
dichloro-28- [chloro(3,4-
dihydroxycyclohex-3-en-1-yl)methoxy]- 
6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26
}.0^{8,29}.0^{11,16}.0^{17,22}.0^{32,37}
]tetraconta- 14,17,19-trien-
10,13,14,15,18,19,20,23,31,39,39- undecol 
ClC(O1)(C2(O)O)C(S(C)(N)O)CC(COC43)C2C5C1C(Cl)CCC5C(O)
OC6C3OC(O)C7CC(O)C(O)=C(O)C7C8=C(O)C(O)=C(O)CC8C(O)
OCC4OC6OC(Cl)C9CC(O)=C(O)CC9 
-123.149 
4 (1R,8S,29R,38S)-31-chloro-28-[(3,4- 
dihydroxycyclohex-3-en-1-yl)methoxy]-
1,35-diethyl-2- methanesulfonyl-39-
methoxy-6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26
}.0^{8,29}.0^{11,16}.0^{17,22}.0^{32,37}
]tetraconta- 14,18,35-trien-
10,13,14,15,18,19,20,23-octol 
ClC(O1)C2CCC(CC)=C(O3)C2C4C(OC)C3(CC)C(S(C)(=O)=O)CC4
COC5C(O6)COC(O)C7CC(O)C(O)=C(O)C7C8C(O)=C(O)C(O)CC8
C(O)OC5C1C6OCC9CC(O)=C(O)CC9 
-127.869 
5 (1S,2E,8S,38S)-34-chloro-28-[(3,4- 
dihydroxycyclohex-3-en-1-yl)methoxy]-1-
ethyl-39- methoxy-35-(methylamino)-2-
(methylimino)- 6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26
}.0^{8,29}.0^{11,16}.0^{17,22}.0^{32,37}
]tetraconta- 14,18,32,34,36-pentaen-
10,13,14,15,18,19,20,23- octol 
Clc([cH]1)c(NC)c2OC(C3OC)(CC)C(=[NH]C)CC(COC54)C3c2c1C
OC6C4OC(O)C7CC(O)C(O)=C(O)C7C8C(O)=C(O)C(O)CC8C(O)O
CC5OC6OCC9CC(O)=C(O)CC9 
-121.035 
6 (1R,2E,8S,38R)-5,34-dibromo-28-[(3,4- 
dihydroxycyclohex-3-en-1-yl)methoxy]-2- 
BrC(OC21)C3CC(=[NH]C)C(O4)CC3C5C4=C(CCC)C(Br)CC5COC
6C1OC(O)C7CCC(O)=C(O)C7C8C(O)C(O)=C(O)CC8COCC2OC6O
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(methylimino)-35-propyl-6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26
}.0^{8,29}.0^{11,16}.0^{17,22}.0^{32,37}
]tetraconta- 14,19,35-triene-
10,14,15,18,19,20-hexol 
CC9CC(O)=C(O)CC9 
 
Table 6: (c) Kaempferol-3-o-glucoside and derivatives at cavity 5 
Sl.No  Ligand Name  SMILES  Rerank Score 
1 Kaempferol-3-o-glucoside  OC(C(CO)O1)C(O)C(O)C1OC2C(O)C3C(O)CC(O)CC3OC2C4CCC(O
)CC4 
-118.36 
2 2-{[4,5-bis(hydroxymethyl)-7-methyl-2-
(2-methyl-4-propylcyclohexyl)-5,6,7,8-
tetrahydrochromen-3-yl]oxy}-6-
(hydroxymethyl)-3-methylpyridin-4-ol 
ClC(C1)CCC(C2)C1N(C)C(=C3CCC(C)CC3)C2Oc(n4)c(C)[cH]c(Cl)c
4CC 
-116.759 
3 7-chloro-3-[(5-chloro-6-ethyl-3-
methylpyridin-2-yl)oxy]-1-methyl-2-(4-
methylcyclohexylidene)- 
decahydroquinoline 
ClC(C1)CCC(C2)C1N(C)C(=C3CCC(C)CC3)C2Oc(n4)c(C)[cH]c(Cl)c
4CC 
-110.413 
    
  
4 (4S)-2-(4-bromocyclohexyl)-3-{[6-(2-
bromoethyl)-4- methoxy-2,3,4,5-
tetrahydro-1$l^{4}-pyridin-2- yl]oxy}-4-
(hydroxymethyl)-5-methyl-4-propyl- 
octahydro-2H-1-benzopyran-7-ol 
BrC(CC1)CCC1C2OC3CC(O)CC(C)C3C(CO)(CCC)C2OC 
([NH]=4)CC(OC)CC=4CCBr 
-111.262 
5 {3-[(4-chloro-3,6-dimethylpyridin-2-
yl)oxy]-5-(hydroxymethyl)-7-methyl-2-
(2-methyl-4-propylcyclohexyl)-5,6,7,8-
tetrahydrochromen-4- 
yl}methanol 
Clc(c1(C))[cH]c(C)nc1Oc2c(CO)c3C(CO)CC(C)Cc3oc2C(CC4)C(C)C
C4CCC 
-97.1581 
6 2-{[4,5-bis(chloromethyl)-7-methyl-2-(2-
methyl-4-propylcyclohexyl)-5,6,7,8-
tetrahydrochromen-3-yl]oxy}-4,6-
dichloro-3-methylpyridine 
ClCc1c2C(CCl)CC(C)Cc2oc(C3CCC(CCC)CC3(C))c1Oc4nc(Cl)[cH]c(
Cl)c4C 
-113.533 
 
Table 6: (d) Gallotannin  and its derivatives at cavity 3 
Sl. No  Ligand Name  SMILES  Rerank Score 
1 Gallotannin  OC1C(OC(C2CC(C(C(C2)O)O)O)O)C(O)C(OC(C3CC(C(C
(C3)O)O)O)O)OC1COC(O)C(C4)CC(O)C(O)C4O 
-128.55 
2 (1R,2Z,8S,38S)-3-amino-2-[(3- 
aminopropyl)(ethyl)imino]-28-[(3,4- 
dihydroxycyclohex-3-en-1-yl)methoxy]-34-imino- 
6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{8,29}
.0^{11,16}.0^{17,22}.0^{32,37}]tetraconta- 
15,19,32(37)-triene-10,14,15,18,19,20-hexol 
OC(OC21)C3CCC(O)C(O)=C3C4C(O)C(O)=C(O)CC4COC
C(O5)C2OCC6C(N)C(=N(CCCN)CC)C(O7)CC6C=8C7CC
(=[NH2])CC=8COC1C5OCC9CC(O)=C(O)CC9 
-81.4704 
3 (1R,8S,38R)-5,34-dibromo-28-[(3,4- 
dihydroxycyclohex-3-en-1-yl)methoxy]-2- 
[ethyl(methyl)amino]-35-propyl-6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{8,29}
.0^{11,16}.0^{17,22}.0^{32,37}]tetraconta- 
15,19,33,35-tetraene-10,14,15,18,19,20-hexol 
BrC(OC21)C3CC(N(C)CC)C(O4)CC3C5C4=C(CCC)C(Br)
=CC5COC6C1OC(O)C7CCC(O)C(O)=C7C8C(O)C(O)=C(
O)CC8COCC2OC6OCC9CC(O)=C(O)CC9 
-99.9452 
4 (1R,2Z,8S,38R)-2-[(3-aminopropyl)(ethyl)imino]- 
5,34-dibromo-28-[(3,4-dihydroxycyclohex-3-en-1- 
yl)methoxy]-6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{8,29}
.0^{11,16}.0^{17,22}.0^{32,37}]tetraconta- 15,19-
diene-10,14,15,18,19,20-hexol 
BrC(OC21)C3CC(=N(CCCN)CC)C(O4)CC3C5C4CC(Br)C
C5COC6C1OC(O)C7CCC(O)C(O)=C7C8C(O)C(O)=C(O)C
C8COCC2OC6OCC9CC(O)=C(O)CC9 
-98.8631 
5 (1S,8S,38S)-5,34-dibromo-35-(diethylamino)-28- 
[(3,4-dihydroxycyclohex-3-en-1-yl)methoxy]- 
6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{8,29}
.0^{11,16}.0^{17,22}.0^{32,37}]tetraconta- 
15,19,32,34,36-pentaene-10,14,15,18,19,20-hexol 
BrC(OC21)C3CCC(O4)CC3c5c4c(N(CC)CC)c(Br)[cH]c5C
OC6C1OC(O)C7CCC(O)C(O)=C7C8C(O)C(O)=C(O)CC8C
OCC2OC6OCC9CC(O)=C(O)CC9 
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6 (1R,8S,38R)-2-[(3-aminopropyl)(ethyl)amino]-28- 
[(3,4-dihydroxycyclohex-3-en-1-yl)methoxy]-34- 
imino-6,9,24,27,30,40- 
hexaoxaoctacyclo[34.3.1.0^{4,38}.0^{7,26}.0^{8,29}
.0^{11,16}.0^{17,22}.0^{32,37}]tetraconta- 3,15,19-
triene-3,10,14,15,18,19,20-heptol 
OC(OC21)C3CCC(O)C(O)=C3C4C(O)C(O)=C(O)CC4COC
C(O5)C2OCC6=C(O)C(N(CCCN)CC)C(O7)CC6C8C7CC(
=[NH2])CC8COC1C5OCC9CC(O)=C(O)CC9 
-99.8931 
 
Table 6: (e) Tiliroside and its derivatives at cavity 1 
Sl. No  Ligand Name  SMILES  Rerank Score 
1 Tiliroside  OC(C(COC(CCC2CCC(CC2)O)O)O1)C(O)C(O)C1OC3C(
O)C4C(O)CC(O)CC4OC3C5CCC(O)CC5 
-134.951 
2 4-(3-{[6-({5-amino-2-[4-(ethylimino)cyclohexyl]- 
4,7-dihydroxy-5,6,7,8-tetrahydrochromen-3- 
yl}methyl)-4-chloro-3,5-dihydroxypyran-2- 
yl]methoxy}-3-hydroxypropyl)cyclohexane-1- 
carboxylic acid 
Clc(c1O)c(O)c(COC(CCC2CCC(CC2)=c(o)o)O)oc1Oc3c(O
)c4C(=[NH2])CC(O)Cc4oc3C(CC5)CCC5=N(C)CC 
 
-86.8885 
3 4-[3-({4-amino-6-[(5-amino-2-{4- 
[ethyl(methyl)amino]cyclohexyl}-4,7-dihydroxy- 
5,6,7,8-tetrahydrochromen-3-yl)oxy]-5-chloro-3- 
hydroxypyran-2-yl}methoxy)-3- 
hydroxypropyl]cyclohexane-1-carboxylic acid 
Clc1c(=[NH2])c(O)c(COC(CCC2CCC(CC2)=c(o)o)O)oc1O
c3c(O)c4C(=[NH2])CC(O)Cc4oc3C(CC5)CCC5=N(C)CC 
 
-128.952 
4 4-(3-{[4-amino-6-({5-amino-4-fluoro-7-hydroxy-2-
[4-(hydroxymethyl)cyclohexyl]-5,6,7,8- 
tetrahydrochromen-3-yl}amino)-3,5-difluoropyran-2-
yl]methoxy}-3-hydroxypropyl)cyclohexane-1- 
carboxylic acid 
Fc(c(COC(CCC2CCC(CC2)=c(o)o)O)o1)c(=[NH2])c(F)c1=
[NH]c3c(F)c4C(=[NH2])CC(O)Cc4oc3C(CC5)CCC5CO 
 
-112.242 
5 5-amino-3-[(6-{[3-(4-aminocyclohexyl)-1- 
hydroxypropoxy]methyl}-4,5-dichloro-3-
hydroxypyran-2- yl)(methyl)-$l^{3}-chloranyl]-2-{4- 
[ethyl(methyl)amino]cyclohexyl}-5,6,7,8- 
tetrahydrochromene-4,7-diol 
Clc(c(COC(CCC2CCC(CC2)=[NH2])O)o1)c(Cl)c(O)c1Clc3
c(O)c4C(=[NH2])CC(O)Cc4oc3C(CC5)CCC5=N(C)CC 
 
-128.181 
6 5-amino-3-[(6-{[3-(3-aminocyclohexyl)-1- 
hydroxypropoxy]methyl}-4,5-dichloro-3-
hydroxypyran-2- 
yl)oxy]-2-[4-(3-hydroxycyclohexyl)cyclohexyl]- 
5,6,7,8-tetrahydrochromene-4,7-diol 
Clc(c(COC(CCC2CC(=[NH2])CCC2)O)o1)c(Cl)c(O)c1Oc3
c(O)c4C(=[NH2])CC(O)Cc4oc3C(CC5)CCC5C(C6)CCCC6
O 
 
-105.166 
 
Table 6: (f) Trachelogenin and its derivatives at cavity 1 
Sl. No  Ligand Name  SMILES  Rerank Score 
1 Trachelogenin  OC1(CC2CC(C(CC2)O)OC)C(O)OCC1CC(C3)
CCC(OC)C3OC 
-107.071 
2 (3R)-2-amino-3-[(4-hydroxy-3-methoxycyclohexyl)methyl]-4-
{[3-(2-hydroxyethyl)-4-(4-methylcyclohexyl)cyclohex-3-en-1-
yl]methyl}oxolan-3-ol 
OC1(CC2CC(C(CC2)O)OC)C(=[NH2])OCC1C
C(CC=3CCO)CCC=3C4CCC(C)CC4 
 
-87.7697 
3 4-{[(3R)-2-amino-3-hydroxy-4-({3- 
[(hydroxymethyl)amino]-4-(4-
methylcyclohexyl)cyclohexyl}methyl)pyrrolidin-3-
yl]methyl}cyclohex-1-ene-1,2-diol 
OC1(CC2CC(=C(CC2)O)O)C(=[NH2])NCC1CC
(CC3=[NH]CO)CCC3C4CCC(C)CC4 
 
-90.1273 
4 4-{[(3R)-2-amino-4-({3-[ethyl(methyl)amino]-4-(4-
methylcyclohexyl)cyclohexyl}methyl)-3- 
hydroxypyrrolidin-3-yl]methyl}cyclohex-1-ene-1,2-diol 
OC1(CC2CC(=C(CC2)O)O)C(=[NH2])NCC1CC
(CC3N(C)CC)CCC3C4CCC(C)CC4 
 
-87.7609 
5 4-{[(3R)-2-amino-4-{[4-(3,4-dichlorocyclohex-3-en-1-yl)-3-
[ethyl(methyl)amino]cyclohexyl]methyl}-3- 
hydroxypyrrolidin-3-yl]methyl}cyclohex-1-ene-1,2-diol 
ClC(=C(Cl)C1)CCC1C(C(N(C)CC)C2)CCC2CC
3CNC(=[NH2])C3(O)CC(C4)CCC(O)=C4O 
 
-89.5052 
6 4-{[(3S)-2-amino-4-{[4-(3,4-dichlorocyclohex-3-en-1-yl)-3-
[ethyl(methyl)amino]cyclohexyl]methyl}-3- 
propylpyrrolidin-3-yl]methyl}cyclohex-1-ene-1,2-diol 
ClC(=C(Cl)C1)CCC1C(C(N(C)CC)C2)CCC2CC
3CNC(=[NH2])C3(CCC)CC(C4)CCC(O)=C4O 
 
-82.9021 
 